Array Biopharma Inc.

Genentech, Inc.

Astrazeneca Ab

Allison L Marlow

Eli M Wallace

Joseph P Lyssikatos

T Brian Hurley

James F Blake

Jeongbeob Seo

Hong Woon Yang

Steven Armen Boyd

Kevin Koch

John Joseph Gaudino

Allen A Thomas

Hong-Woon Yang

Hongqi Tian

Jason De Meese

Gabrielle R Kolakowski

Huifen Chen

Mark Joseph Chicarelli

Li Ren

Jacob Bradley Schwarz

Wendy B Young

Frederick Cohen

Peter J Mohr

Kin Chiu Fong

John David Pittam

Rustam Ferdinand Garrey

John Leonard

Robert J Kaus

Steven Mark Wenglowsky

Christopher Stephen Siedem

Richard Storey

Jim Blake

Brian Hurley

Jason Demeese

Tomas Kaplan

Rebecca Jane Booth

Mark Richard Fielding

Christopher S Siedem

Brian T Hurley

Richard Anthony Storey

Hoon Woon Yang

Compounds having the formula I wherein Z, ZZZ, R, Rand Rand as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Serine/threonine kinase inhibitors

Disclosed are methods for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals, comprising administering to a mammal in heed thereof a pharmaceutical composition comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an anti-tumor agent or in combination with radiation therapy.

Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal

Disclosed are crystalline forms of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide

Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, Rand R, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases and inflammatory conditions in mammals and pharmaceutical compositions containing such compounds.

6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof

Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, R, W, and X are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Heterocyclic inhibitors of MEK and methods of use

Disclosed are pharmaceutical compositions comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of using such compositions for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals.

Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof

Disclosed are pharmaceutical compositions comprising 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of using such compositions for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals.

Disclosed are methods of treating a hyperproliferative disorder or a disease related to vasculogenesis or angiogenesis in a mammal, comprising administering to said mammal an effective amount of a compound of the formula or a pharmaceutically accepted salt thereof, wherein A, R, R, R, R, and Rare as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals.

Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein A, R, R, R, R, and Rare as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the Formulas I and V and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, Rand R, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof

Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, Rand R, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Substituted pyridazines inhibitors of MEK

Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Heterobicyclic thiophene compounds and methods of use

Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R, R, R, R, Rand Rare as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, R, and W are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative and inflammatory diseases in mammals and pharmaceutical compositions containing such compounds.

Growing community of inventors

Louisville, CO, United States of America

Allison L Marlow